8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 30, 2026·SEC
Halozyme Therapeutics, Inc.(HALO)Earnings, Financials & Key Ratios
HALO•NASDAQ
26.0× P/E·Price updated May 30, 2026
AboutHalozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.Show more
- Revenue$1.4B+37.6%
- EBITDA$904M+42.9%
- Net Income$317M-28.6%
- EPS (Diluted)2.56-25.4%
- Gross Margin78.13%-7.3%
- EBITDA Margin64.75%+3.9%
- Operating Margin58.45%+7.6%
- Net Margin22.69%-48.1%
- ROE153.59%-22.6%
- ROIC32.13%+25.0%
- Debt/Equity43.89+960.5%
- Interest Coverage45.03+41.7%
HALO Key Insights
Halozyme Therapeutics, Inc. (HALO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 191.4%
- ✓Strong 5Y profit CAGR of 19.7%
- ✓FCF machine: 46.2% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 39.2%
- ✓Share count reduced 4.3% through buybacks
✗Weaknesses
- ✗High debt to equity ratio of 43.9x
- ✗Expensive at 168.9x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when HALO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HALO Price & Volume
Halozyme Therapeutics, Inc. (HALO) stock price & volume — 10-year historical chart
Loading chart...
HALO Growth Metrics
Halozyme Therapeutics, Inc. (HALO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years26.32%
5 Years39.16%
3 Years28.38%
TTM39.12%
Profit CAGR
10 Years-
5 Years19.68%
3 Years16.17%
TTM-28.13%
EPS CAGR
10 Years-
5 Years22.98%
3 Years21.14%
TTM-26.06%
Return on Capital
10 Years14.1%
5 Years31.52%
3 Years29.86%
Last Year38.21%
HALO Recent Earnings
Halozyme Therapeutics, Inc. (HALO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 11, 2026EPS
$1.60
Est $1.54
+3.9%
Revenue
$377M
Est $359M
+5.0%
Q1 2026
Feb 17, 2026EPS
$0.24
Est $2.15
-111.2%
Revenue
$452M
Est $436M
+3.7%
Q4 2025
Nov 3, 2025EPS
$1.72
Est $1.63
+5.5%
Revenue
$354M
Est $447M
-20.7%
Q3 2025
Aug 5, 2025EPS
$1.54
Est $1.23
+25.2%
Revenue
$326M
Est $331M
-1.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $1.60vs $1.54+3.9% | $377Mvs $359M+5.0% |
| Q1 2026 | Feb 17, 2026 | $0.24vs $2.15-111.2% | $452Mvs $436M+3.7% |
| Q4 2025 | Nov 3, 2025 | $1.72vs $1.63+5.5% | $354Mvs $447M-20.7% |
| Q3 2025 | Aug 5, 2025 | $1.54vs $1.23+25.2% | $326Mvs $331M-1.5% |
Based on last 12 quarters of dataView full earnings history →
HALO Peer Comparison
Halozyme Therapeutics, Inc. (HALO) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ALNY | 40.29B | 301.98 | 129.61 | 65.19% | 13.46% | 98.29% | 1.62 | |
 IONS | 12.64B | 76.50 | -32.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ARWR | 10.97B | 77.91 | -6386.07 | 232.58% | -48.38% | -55.09% | 0.73 | |
 EXEL | 12.82B | 50.48 | 18.16 | 6.98% | 35.08% | 40.21% | 0.08 | |
 INVA | 1.58B | 21.42 | 6.49 | 18.52% | 118.91% | 47.59% | 0.23 | |
 RCUS | 2.55B | 25.34 | -7.70 | -4.26% | -156.36% | -68.97% | 0.16 | |
 ABBV | 384.85B | 217.58 | 91.81 | 8.57% | 6.91% | 62.15% | ||
 AMGN | 181.76B | 336.79 | 23.67 | 9.92% | 20.95% | 89.41% | 6.31 |
Compare HALO vs Peers
Halozyme Therapeutics, Inc. (HALO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HALO Income Statement
Halozyme Therapeutics, Inc. (HALO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 316.61M | 151.86M | 195.99M | 267.59M | 443.31M | 660.12M | 829.25M | 1.02B | 1.4B | 1.51B |
Revenue Growth % | 115.84% | -52.04% | 29.06% | 36.53% | 65.67% | 48.91% | 25.62% | 22.44% | 37.55% | 39.12% |
Cost of Goods Sold | 31.15M | 10.14M | 45.55M | 43.37M | 81.41M | 139.3M | 192.36M | 159.42M | 305.44M | 348.02M |
COGS % of Revenue | 9.84% | 6.67% | 23.24% | 16.21% | 18.36% | 21.1% | 23.2% | 15.7% | 21.87% | - |
Gross Profit | 285.46M▲ 0% | 141.73M▼ 50.4% | 150.45M▲ 6.2% | 224.23M▲ 49.0% | 361.9M▲ 61.4% | 520.81M▲ 43.9% | 636.89M▲ 22.3% | 855.91M▲ 34.4% | 1.09B▲ 27.5% | 1.16B▲ 0% |
Gross Margin % | 90.16% | 93.33% | 76.76% | 83.79% | 81.64% | 78.9% | 76.8% | 84.3% | 78.13% | 76.93% |
Gross Profit Growth % | 151.54% | -50.35% | 6.15% | 49.04% | 61.4% | 43.91% | 22.29% | 34.39% | 27.49% | - |
Operating Expenses | 204.46M | 211.06M | 218.06M | 79.97M | 86M | 253.28M | 299.32M | 304.43M | 274.88M | 301.16M |
OpEx % of Revenue | 64.58% | 138.98% | 111.26% | 29.89% | 19.4% | 38.37% | 36.09% | 29.98% | 19.68% | - |
Selling, General & Admin | 53.82M | 60.8M | 77.25M | 45.74M | 50.32M | 143.53M | 149.18M | 154.34M | 193.39M | 208.91M |
SG&A % of Revenue | 17% | 40.04% | 39.42% | 17.09% | 11.35% | 21.74% | 17.99% | 15.2% | 13.85% | - |
Research & Development | 150.64M | 150.25M | 140.8M | 34.24M | 35.67M | 66.61M | 76.36M | 79.05M | 81.49M | 92.25M |
R&D % of Revenue | 47.58% | 98.94% | 71.84% | 12.79% | 8.05% | 10.09% | 9.21% | 7.79% | 5.83% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 43.15M | 73.77M | 71.05M | 0 | 0 |
Operating Income | 81M▲ 0% | -69.33M▼ 185.6% | -67.61M▲ 2.5% | 144.25M▲ 313.4% | 275.9M▲ 91.3% | 267.53M▼ 3.0% | 337.57M▲ 26.2% | 551.48M▲ 63.4% | 816.29M▲ 48.0% | 859.27M▲ 0% |
Operating Margin % | 25.58% | -45.65% | -34.5% | 53.91% | 62.24% | 40.53% | 40.71% | 54.32% | 58.45% | 56.96% |
Operating Income Growth % | 197.35% | -185.59% | 2.48% | 313.36% | 91.26% | -3.03% | 26.18% | 63.36% | 48.02% | - |
EBITDA | 83.16M | -66.94M | -63.54M | 147.54M | 278.9M | 317.17M | 422.43M | 632.79M | 904.34M | 960.61M |
EBITDA Margin % | 26.27% | -44.08% | -32.42% | 55.14% | 62.91% | 48.05% | 50.94% | 62.32% | 64.75% | 63.68% |
EBITDA Growth % | 202.92% | -180.49% | 5.08% | 332.19% | 89.03% | 13.72% | 33.19% | 49.8% | 42.91% | 41.46% |
D&A (Non-Cash Add-back) | 2.16M | 2.39M | 4.07M | 3.28M | 3M | 49.64M | 84.86M | 81.31M | 88.05M | 101.34M |
EBIT | 81M | -69.33M | -60.62M | 149.68M | 256.04M | 265.87M | 367.09M | 575.23M | 816.29M | 859.27M |
Net Interest Income | -21.98M | -18.04M | -11.63M | -20.38M | -7.53M | -16.95M | -18.76M | -18.09M | -18.13M | -5.57M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.54M |
Interest Expense | 21.98M | 18.04M | 11.63M | 20.38M | 7.53M | 16.95M | 18.76M | 18.09M | 18.13M | 19.11M |
Other Income/Expense | -19.39M | -10.46M | -4.64M | -14.95M | -27.38M | -18.61M | 10.76M | 5.66M | -349.42M | -355.9M |
Pretax Income | 61.61M▲ 0% | -79.79M▼ 229.5% | -72.25M▲ 9.5% | 129.3M▲ 279.0% | 248.52M▲ 92.2% | 248.92M▲ 0.2% | 348.33M▲ 39.9% | 557.13M▲ 59.9% | 466.88M▼ 16.2% | 503.37M▲ 0% |
Pretax Margin % | 19.46% | -52.54% | -36.86% | 48.32% | 56.06% | 37.71% | 42.01% | 54.87% | 33.43% | 33.37% |
Income Tax | -1.36M | 537K | -11K | 217K | -154.19M | 46.79M | 66.73M | 113.04M | 149.99M | 154.53M |
Effective Tax Rate % | -2.21% | -0.67% | 0.02% | 0.17% | -62.04% | 18.8% | 19.16% | 20.29% | 32.13% | 30.7% |
Net Income | 62.97M▲ 0% | -80.33M▼ 227.6% | -72.24M▲ 10.1% | 129.09M▲ 278.7% | 402.71M▲ 212.0% | 202.13M▼ 49.8% | 281.59M▲ 39.3% | 444.09M▲ 57.7% | 316.89M▼ 28.6% | 348.84M▲ 0% |
Net Margin % | 19.89% | -52.9% | -36.86% | 48.24% | 90.84% | 30.62% | 33.96% | 43.74% | 22.69% | 23.13% |
Net Income Growth % | 161.12% | -227.57% | 10.07% | 278.69% | 211.97% | -49.81% | 39.31% | 57.71% | -28.64% | -28.13% |
Net Income (Continuing) | 62.97M | -80.33M | -72.24M | 129.09M | 402.71M | 202.13M | 281.59M | 444.09M | 316.89M | 348.84M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.45▲ 0% | -0.56▼ 224.4% | -0.50▲ 10.7% | 0.91▲ 282.0% | 2.74▲ 201.1% | 1.44▼ 47.4% | 2.10▲ 45.8% | 3.43▲ 63.3% | 2.56▼ 25.4% | 2.84▲ 0% |
EPS Growth % | 155.56% | -224.44% | 10.71% | 282% | 201.1% | -47.45% | 45.83% | 63.33% | -25.36% | -26.06% |
EPS (Basic) | 0.46 | -0.56 | -0.50 | 0.95 | 2.86 | 1.48 | 2.13 | 3.50 | 2.64 | - |
Diluted Shares Outstanding | 139.07M | 143.6M | 144.33M | 141.46M | 146.8M | 140.61M | 134.2M | 129.42M | 123.9M | 122.88M |
Basic Shares Outstanding | 136.42M | 143.45M | 144.33M | 136.21M | 140.65M | 136.84M | 131.93M | 126.83M | 119.84M | 118.14M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
HALO Balance Sheet
Halozyme Therapeutics, Inc. (HALO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 510.37M | 427.85M | 543.44M | 554.76M | 926.29M | 739.01M | 746.42M | 1.09B | 825.21M | 1B |
Cash & Short-Term Investments | 469.21M | 354.53M | 421.26M | 368.01M | 740.92M | 362.79M | 336M | 596.07M | 142.82M | 318.62M |
Cash Only | 168.74M | 57.94M | 120.18M | 147.7M | 118.72M | 234.19M | 118.37M | 115.85M | 133.82M | 309.75M |
Short-Term Investments | 300.47M | 296.59M | 301.08M | 220.31M | 622.2M | 128.6M | 217.63M | 480.22M | 9M | 8.87M |
Accounts Receivable | 22.13M | 30M | 59.44M | 97.73M | 90.97M | 231.07M | 234.21M | 308.45M | 441.27M | 457.99M |
Days Sales Outstanding | 25.52 | 72.12 | 110.7 | 133.3 | 74.9 | 127.77 | 103.09 | 110.89 | 115.33 | 94.47 |
Inventory | 5.15M | 22.63M | 29.36M | 60.75M | 53.91M | 100.12M | 127.6M | 141.86M | 176.47M | 155.47M |
Days Inventory Outstanding | 60.29 | 814.73 | 235.28 | 511.28 | 241.69 | 262.34 | 242.12 | 324.8 | 210.89 | 183.34 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 45.02M | 48.61M | 38.95M | 64.64M | 70.96M |
Total Non-Current Assets | 9.57M | 12.4M | 22.44M | 25.16M | 178.14M | 1.1B | 986.85M | 978.14M | 1.7B | 1.67B |
Property, Plant & Equipment | 3.52M | 7.46M | 10.86M | 10.59M | 8.79M | 75.57M | 74.94M | 75.03M | 82.14M | 82.23M |
Fixed Asset Turnover | 89.95x | 20.34x | 18.06x | 25.26x | 50.41x | 8.74x | 11.06x | 13.53x | 17.00x | 19.63x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 409.05M | 416.82M | 416.82M | 580.36M | 582.32M |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 546.65M | 472.88M | 401.83M | 981.47M | 951.96M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 6.05M | 4.93M | 11.58M | 14.57M | 13.91M | 26.8M | 17.82M | 80.6M | 56.15M | 53.17M |
Total Assets | 519.95M▲ 0% | 440.25M▼ 15.3% | 565.87M▲ 28.5% | 579.92M▲ 2.5% | 1.1B▲ 90.4% | 1.84B▲ 66.7% | 1.73B▼ 5.9% | 2.06B▲ 19.1% | 2.53B▲ 22.4% | 2.67B▲ 0% |
Asset Turnover | 0.61x | 0.34x | 0.35x | 0.46x | 0.40x | 0.36x | 0.48x | 0.49x | 0.55x | 0.64x |
Asset Growth % | 98.82% | -15.33% | 28.54% | 2.48% | 90.44% | 66.74% | -5.88% | 19.05% | 22.38% | 53.22% |
Total Current Liabilities | 131.33M | 149.36M | 85.64M | 421.38M | 117.15M | 130.79M | 112.49M | 139.1M | 177.09M | 363.21M |
Accounts Payable | 7.95M | 4.08M | 6.43M | 1.93M | 1.54M | 17.69M | 11.82M | 10.25M | 20.9M | 14.1M |
Days Payables Outstanding | 93.12 | 146.89 | 51.56 | 16.23 | 6.91 | 46.36 | 22.42 | 23.47 | 24.97 | 18.1 |
Short-Term Debt | 77.21M | 91.51M | 19.54M | 397.23M | 89.42M | 13.33M | 0 | 0 | 0 | 208.74M |
Deferred Revenue (Current) | 6.57M | 4.25M | 4.01M | 1.75M | 1.75M | 3.25M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | -3.25M | 0 | 0 | 156.19M | 140.37M |
Current Ratio | 3.89x | 2.86x | 6.35x | 1.32x | 7.91x | 5.65x | 6.64x | 7.80x | 4.66x | 4.66x |
Quick Ratio | 3.85x | 2.71x | 6.00x | 1.17x | 7.45x | 4.88x | 5.50x | 6.78x | 3.66x | 3.66x |
Cash Conversion Cycle | -7.31 | 739.96 | 294.42 | 628.36 | 309.68 | 343.75 | 322.79 | 412.22 | 301.24 | 259.7 |
Total Non-Current Liabilities | 180.25M | 42M | 388.47M | 7.49M | 790.33M | 1.54B | 1.54B | 1.56B | 2.3B | 2.09B |
Long-Term Debt | 125.14M | 34.87M | 383.05M | 0 | 787.25M | 1.49B | 1.5B | 1.51B | 2.14B | 1.94B |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42.92M | 98.67M |
Other Non-Current Liabilities | 814K | 2.12M | 4.18M | 3.47M | 544K | 45.91M | 37.72M | 54.76M | 113.86M | 106.45M |
Total Liabilities | 311.58M | 191.36M | 474.11M | 428.88M | 907.48M | 1.67B | 1.65B | 1.7B | 2.48B | 2.45B |
Total Debt | 202.35M | 126.38M | 402.59M | 397.23M | 876.67M | 1.51B | 1.5B | 1.51B | 2.14B | 2.14B |
Net Debt | 33.61M | 68.44M | 282.41M | 249.53M | 757.96M | 1.27B | 1.38B | 1.39B | 2.01B | 1.83B |
Debt / Equity | 0.97x | 0.51x | 4.39x | 2.63x | 4.45x | 8.87x | 17.89x | 4.14x | 43.89x | 43.89x |
Debt / EBITDA | 2.43x | - | - | 2.69x | 3.14x | 4.75x | 3.55x | 2.38x | 2.37x | 2.23x |
Net Debt / EBITDA | 0.40x | - | - | 1.69x | 2.72x | 4.01x | 3.27x | 2.20x | 2.22x | 2.22x |
Interest Coverage | 3.68x | -3.84x | -5.21x | 7.35x | 34.02x | 15.69x | 19.57x | 31.79x | 45.03x | 44.97x |
Total Equity | 208.37M▲ 0% | 248.89M▲ 19.4% | 91.77M▼ 63.1% | 151.05M▲ 64.6% | 196.95M▲ 30.4% | 169.8M▼ 13.8% | 83.81M▼ 50.6% | 363.82M▲ 334.1% | 48.81M▼ 86.6% | 219.64M▲ 0% |
Equity Growth % | 741.5% | 19.45% | -63.13% | 64.6% | 30.39% | -13.79% | -50.64% | 334.11% | -86.58% | -114.76% |
Book Value per Share | 1.50 | 1.73 | 0.64 | 1.07 | 1.34 | 1.21 | 0.62 | 2.81 | 0.39 | 1.79 |
Total Shareholders' Equity | 208.37M | 248.89M | 91.77M | 151.05M | 196.95M | 169.8M | 83.81M | 363.82M | 48.81M | 219.64M |
Common Stock | 143K | 145K | 137K | 135K | 138K | 135K | 127K | 123K | 118K | 118K |
Retained Earnings | -522.37M | -531.44M | -603.68M | -474.59M | -58.91M | 143.22M | 90.55M | 359.87M | 54.79M | 204.84M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -450K | -277K | 240K | 22K | -620K | -922K | -9.28M | 3.83M | -18.09M | -12.7M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HALO Cash Flow Statement
Halozyme Therapeutics, Inc. (HALO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 134.05M | -49.5M | -85.42M | 55.45M | 299.44M | 240.11M | 388.57M | 479.06M | 651.56M | 651.56M |
Operating CF Margin % | 42.34% | -32.6% | -43.58% | 20.72% | 67.55% | 36.37% | 46.86% | 47.18% | 46.65% | - |
Operating CF Growth % | 366.07% | -136.93% | -72.57% | 164.92% | 439.98% | -19.81% | 61.83% | 23.29% | 36.01% | 173% |
Net Income | 62.97M | -80.33M | -72.24M | 129.09M | 402.71M | 202.13M | 281.59M | 444.09M | 316.89M | 348.84M |
Depreciation & Amortization | 2.16M | 2.39M | 6.55M | 17.42M | 6.64M | 57.48M | 84.86M | 88.66M | 88.05M | 105.05M |
Stock-Based Compensation | 30.67M | 35.7M | 34.78M | 17.2M | 20.82M | 24.4M | 36.62M | 43.38M | 51.56M | 40.96M |
Deferred Taxes | -257K | -3.08M | 0 | 0 | 0 | 0 | 34.51M | 0 | 634K | -13.34M |
Other Non-Cash Items | 17.82M | 1.7M | 666K | -41.1M | -133.3M | 66.59M | -10.33M | 39.2M | 346.68M | 344.98M |
Working Capital Changes | 20.69M | -5.87M | -55.18M | -67.16M | 2.57M | -110.49M | -38.67M | -136.27M | -152.26M | -149.07M |
Change in Receivables | -6.45M | 11.61M | -29.44M | -38.29M | 6.75M | -83.94M | -3.34M | -74.25M | -128.06M | -151.44M |
Change in Inventory | 9.48M | -17.48M | -6.73M | -31.39M | 7.37M | -17.48M | -26.88M | -67.38M | 2.55M | 30.52M |
Change in Payables | 15.63M | -278.49M | 0 | 0 | 0 | 0 | -12.55M | 0 | 0 | 0 |
Cash from Investing | -163.73M | 2.49M | -5.55M | 78.35M | -406.29M | -487M | -96.91M | -262.72M | -545.81M | -458.27M |
Capital Expenditures | -1.35M | -4.66M | -4.04M | -2.5M | -1.46M | -4.81M | -15.29M | -10.7M | -6.97M | -9.76M |
CapEx % of Revenue | 0.43% | 3.07% | 2.06% | 0.94% | 0.33% | 0.73% | 1.84% | 1.05% | 0.5% | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | -999.12M | 0 | 0 | -725.97M | -1.01B |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -162.38M | 7.16M | -1.51M | 80.86M | -404.83M | 516.92M | 0 | -252.03M | -287.77M | 290.99M |
Cash from Financing | 131.66M | -63.8M | 153.22M | -106.28M | 77.86M | 362.37M | -407.99M | -218.86M | -85.17M | -83.47M |
Debt Issued (Net) | -15.99M | -77.52M | 339.27M | -19.56M | 415.81M | 624.55M | -13.48M | 0 | 235.37M | 235.37M |
Equity Issued (Net) | 134.87M | 0 | -200M | -150.12M | -350.06M | -200M | -402.38M | -250M | -320.54M | -334.9M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -200M | -150.12M | -350.06M | -200M | -402.38M | -250M | -342.37M | -339.05M |
Other Financing | 12.78M | 13.72M | 13.95M | 63.39M | 12.11M | -62.17M | 7.88M | 31.14M | 0 | 16.07M |
Net Change in Cash | 101.98M▲ 0% | -110.8M▼ 208.7% | 62.24M▲ 156.2% | 27.52M▼ 55.8% | -28.98M▼ 205.3% | 115.48M▲ 498.4% | -116.33M▼ 200.7% | -2.52M▲ 97.8% | 20.57M▲ 916.3% | 133.42M▲ 0% |
Free Cash Flow | 132.7M▲ 0% | -54.16M▼ 140.8% | -89.46M▼ 65.2% | 52.95M▲ 159.2% | 297.98M▲ 462.8% | 235.3M▼ 21.0% | 373.28M▲ 58.6% | 468.37M▲ 25.5% | 644.59M▲ 37.6% | 667.65M▲ 0% |
FCF Margin % | 41.91% | -35.67% | -45.65% | 19.79% | 67.22% | 35.65% | 45.01% | 46.13% | 46.15% | 44.26% |
FCF Growth % | 347.95% | -140.82% | -65.17% | 159.19% | 462.76% | -21.04% | 58.64% | 25.47% | 37.62% | 34.67% |
FCF per Share | 0.95 | -0.38 | -0.62 | 0.37 | 2.03 | 1.67 | 2.78 | 3.62 | 5.20 | 5.20 |
FCF Conversion (FCF/Net Income) | 2.13x | 0.62x | 1.18x | 0.43x | 0.74x | 1.19x | 1.38x | 1.08x | 2.06x | 1.91x |
Interest Paid | 20.3M | 16.89M | 9.03M | 6.53M | 3.3M | 6.11M | 11.41M | 10.56M | 0 | 0 |
Taxes Paid | 3.02M | 220K | 0 | 0 | 0 | 0 | 31.76M | 0 | 0 | 0 |
HALO Key Ratios
Halozyme Therapeutics, Inc. (HALO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 71.6% | -35.14% | -42.41% | 106.33% | 231.44% | 110.23% | 222.07% | 198.42% | 153.59% | 126.27% |
| Return on Invested Capital (ROIC) | 33.81% | -18.59% | -14.67% | 27.93% | 30.53% | 16.74% | 17.42% | 25.7% | 32.13% | 32.13% |
| Gross Margin | 90.16% | 93.33% | 76.76% | 83.79% | 81.64% | 78.9% | 76.8% | 84.3% | 78.13% | 76.93% |
| Net Margin | 19.89% | -52.9% | -36.86% | 48.24% | 90.84% | 30.62% | 33.96% | 43.74% | 22.69% | 23.13% |
| Debt / Equity | 0.97x | 0.51x | 4.39x | 2.63x | 4.45x | 8.87x | 17.89x | 4.14x | 43.89x | 43.89x |
| Interest Coverage | 3.68x | -3.84x | -5.21x | 7.35x | 34.02x | 15.69x | 19.57x | 31.79x | 45.03x | 44.97x |
| FCF Conversion | 2.13x | 0.62x | 1.18x | 0.43x | 0.74x | 1.19x | 1.38x | 1.08x | 2.06x | 1.91x |
| Revenue Growth | 115.84% | -52.04% | 29.06% | 36.53% | 65.67% | 48.91% | 25.62% | 22.44% | 37.55% | 39.12% |
Related:HALO Dividend History·HALO Revenue History·HALO Price History·HALO P/E History·HALO Financial Ratios·HALO Institutional Holders
HALO SEC Filings & Documents
Halozyme Therapeutics, Inc. (HALO) SEC filings — annual & quarterly reports (10-K, 10-Q)
HALO Frequently Asked Questions
Halozyme Therapeutics, Inc. (HALO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Halozyme Therapeutics, Inc. (HALO) reported $1.51B in revenue for fiscal year 2025. This represents a 6110728% increase from $0.0M in 2001.
Halozyme Therapeutics, Inc. (HALO) grew revenue by 37.6% over the past year. This is strong growth.
Yes, Halozyme Therapeutics, Inc. (HALO) is profitable, generating $348.8M in net income for fiscal year 2025 (22.7% net margin).
Dividend & Returns
Halozyme Therapeutics, Inc. (HALO) has a return on equity (ROE) of 153.6%. This is excellent, indicating efficient use of shareholder capital.
Halozyme Therapeutics, Inc. (HALO) generated $667.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.